BCL9 and neoplasm: In conclusion, this study presents a nanotechnology-enabled strategy to overcome longstanding barriers in peptide drug delivery and demonstrates the feasibility of targeting β-catenin/BCL9 interactions to suppress tumor progression and enhance immunotherapy responsiveness.